Celcuity Will Present Clinical Trial Data in Madrid
Minneapolis-based Celcuity will share new study results at the upcoming ESMO Congress in October.
Updated on Oct. 5, 2026 in Cancer
Live Poll
Does medical research presented at major conferences increase your trust in new cancer treatment options?
Minneapolis-based Celcuity is scheduled to present clinical trial data at the ESMO Congress 2026, held in Madrid from October 23-27. The company will showcase findings through one oral presentation and three poster sessions.
Why it matters
The presentations are expected to offer insight into the progress of Celcuity's ongoing oncology research, including specific studies on breast and prostate cancer treatments.
Celcuity will feature four distinct presentations at the conference, including oral session LBA 16 and three posters numbered 2237P, 1873P, and 57TiP. These figures represent the company's total planned data release for the October event.
The players
Celcuity
This is a Minneapolis-based biotechnology company focused on developing targeted therapies for cancer patients.
ESMO Congress
This is an annual international medical conference organized by the European Society for Medical Oncology.
The details
Celcuity, headquartered in Minneapolis, will present updated results from its VIKTORIA-1 study during a late-breaking oral session. Additional posters will detail trials involving gedatolisib for both breast and prostate cancer patients.
Timeline
October 19, 2026: Abstracts become available online via the ESMO website.
October 23, 2026: Poster presentation for the prostate cancer study takes place.
October 24, 2026: Oral presentation and two additional poster sessions occur.
The Big Picture
This data release updates the progress of the VIKTORIA-1 study by providing new, late-breaking clinical results. The findings represent the latest phase in the company's efforts to advance targeted oncology research.
The upcoming presentations offer a preview of potential future treatment options for breast and prostate cancer. Patients and healthcare providers may gain a better understanding of how these experimental therapies could eventually fit into standard clinical care.
The takeaway
These presentations mark a critical milestone in the development of targeted therapies for oncology patients. Interested parties can monitor the ESMO platform to review the findings once the abstracts are published.
Further reading
For more information on ongoing developments in oncology, visit the Cancer section.
Live Poll
Does medical research presented at major conferences increase your trust in new cancer treatment options?
